Drug Profile
Bentracimab - SFJ Pharmaceuticals
Alternative Names: MEDI-2452; PB-2452Latest Information Update: 02 Feb 2024
Price :
$50
*
At a glance
- Originator AstraZeneca
- Developer PhaseBio Pharmaceuticals; SFJ Pharmaceuticals
- Class Antibodies; Antihaemorrhagics; Fab fragments; Monoclonal antibodies
- Mechanism of Action Platelet aggregation modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Haemorrhage
Most Recent Events
- 22 Jan 2024 PhaseBio Pharmaceuticals in collaboration with SFJ Pharmaceuticals terminates a phase I trial in Haemorrhage (In volunteers) in China (IV) (NCT05162131)
- 17 Jan 2023 SFJ Pharmaceuticals enters into purchasing and asset transfer agreement with PhaseBio Pharmaceuticals for bentracimab
- 17 Jan 2023 SFJ Pharmaceuticals announces intention to submit BLA to the US FDA for Haemorrhage in mid 2023